Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments. Based on a cell’s natural mechanism for eliminating diseased proteins, this therapy can combat hard-to-treat ...

Thousands of molecules in the body are known to influence disease, but creating medicines that can interact effectively with most of them is a challenging task. It’s been estimated that out of roughly ...

Research co-led by University of Toronto researchers and Insilico Medicine has demonstrated the potential of quantum computing and artificial intelligence to transform the drug discovery pipeline. "It ...

The term 'undruggable' refers to proteins or targets that are challenging to target with conventional drugs. In recent years, researchers have made progress in developing drugs that can interact with ...

In 2020, Jennifer Doudna won the Nobel Prize in chemistry for her work on the CRISPR-Cas9 gene-editing technology that allows scientists to precisely modify DNA by cutting it at specific locations.

Proteins that are commonly mutated and overexpressed in cancers are called oncoproteins and are typical targets for cancer therapies. Cancer treatment faces significant challenges due to the presence ...

For the first time, scientists have identified promising drug candidates that bind irreversibly with a notoriously undruggable cancer protein target, permanently blocking it. Transcription factors are ...

Because its induced proximity platform is a key piece of developing multispecific medicines, Amgen is investing heavily in the platform, with the current focus on expanding its team. (iStock / Getty ...

Armed with sophisticated chemistry and fresh approaches to drug design, researchers are closing in on innovative strategies to undermine a cancer-causing mutant protein once considered ‘undruggable’.

A new spinout from Monash University in Melbourne, Australia, is tackling biology to better understand immune cell function and to find targets that were thought to be undruggable. Onko-innate ...

Phase I/II trial of RVU120 (SEL120), a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting ...